Value of MRI - T2 Mapping to Differentiate Clinically Significant Prostate Cancer.
Multiparametric prostate MRI
Prostate cancer
Quantitative imaging
T2 mapping
Journal
Journal of imaging informatics in medicine
ISSN: 2948-2933
Titre abrégé: J Imaging Inform Med
Pays: Switzerland
ID NLM: 9918663679206676
Informations de publication
Date de publication:
26 Jun 2024
26 Jun 2024
Historique:
received:
16
11
2023
accepted:
23
05
2024
revised:
21
05
2024
medline:
27
6
2024
pubmed:
27
6
2024
entrez:
26
6
2024
Statut:
aheadofprint
Résumé
Standardized reporting of multiparametric prostate MRI (mpMRI) is widespread and follows international standards (Pi-RADS). However, quantitative measurements from mpMRI are not widely comparable. Although T2 mapping sequences can provide repeatable quantitative image measurements and extract reliable imaging biomarkers from mpMRI, they are often time-consuming. We therefore investigated the value of quantitative measurements on a highly accelerated T2 mapping sequence, in order to establish a threshold to differentiate benign from malignant lesions. For this purpose, we evaluated a novel, highly accelerated T2 mapping research sequence that enables high-resolution image acquisition with short acquisition times in everyday clinical practice. In this retrospective single-center study, we included 54 patients with clinically indicated MRI of the prostate and biopsy-confirmed carcinoma (n = 37) or exclusion of carcinoma (n = 17). All patients had received a standard of care biopsy of the prostate, results of which were used to confirm or exclude presence of malignant lesions. We used the linear mixed-effects model-fit by REML to determine the difference between mean values of cancerous tissue and healthy tissue. We found good differentiation between malignant lesions and normal appearing tissue in the peripheral zone based on the mean T2 value. Specifically, the mean T2 value for tissue without malignant lesions was (151.7 ms [95% CI: 146.9-156.5 ms] compared to 80.9 ms for malignant lesions [95% CI: 67.9-79.1 ms]; p < 0.001). Based on this assessment, a limit of 109.2 ms is suggested. Aditionally, a significant correlation was observed between T2 values of the peripheral zone and PI-RADS scores (p = 0.0194). However, no correlation was found between the Gleason Score and the T2 relaxation time. Using REML, we found a difference of -82.7 ms in mean values between cancerous tissue and healthy tissue. We established a cut-off-value of 109.2 ms to accurately differentiate between malignant and non-malignant prostate regions. The addition of T2 mapping sequences to routine imaging could benefit automated lesion detection and facilitate contrast-free multiparametric MRI of the prostate.
Identifiants
pubmed: 38926263
doi: 10.1007/s10278-024-01150-6
pii: 10.1007/s10278-024-01150-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : FKZ: 01KX2121
Organisme : Bundesministerium für Bildung und Forschung
ID : FKZ: 01KX2121
Organisme : Bundesministerium für Bildung und Forschung
ID : FKZ: 01KX2121
Organisme : Bundesministerium für Bildung und Forschung
ID : FKZ: 01KX2121
Organisme : Bundesministerium für Bildung und Forschung
ID : FKZ: 01KX2121
Organisme : Bundesministerium für Bildung und Forschung
ID : FKZ: 01KX2121
Organisme : Bundesministerium für Bildung und Forschung
ID : FKZ: 01KX2121
Informations de copyright
© 2024. The Author(s).
Références
Gandaglia G, Leni R, Bray F, et al. Epidemiology and prevention of prostate cancer. Eur Urol Oncol. 2021;4(6):877-892. https://doi.org/10.1016/j.euo.2021.09.006
doi: 10.1016/j.euo.2021.09.006
pubmed: 34716119
Nguyen-Nielsen M, Borre M. Diagnostic and therapeutic strategies for prostate cancer. Semin Nucl Med. 2016;46(6):484-490. https://doi.org/10.1053/j.semnuclmed.2016.07.002
doi: 10.1053/j.semnuclmed.2016.07.002
pubmed: 27825428
Mai J, Abubrig M, Lehmann T, et al. T2 mapping in prostate cancer. Invest Radiol. 2019;54(3):146-152. https://doi.org/10.1097/RLI.0000000000000520
doi: 10.1097/RLI.0000000000000520
pubmed: 30394962
Grivas N, Lardas M, Espinós EL, et al. Prostate Cancer Detection Percentages of Repeat Biopsy in Patients with Positive Multiparametric Magnetic Resonance Imaging (Prostate Imaging Reporting and Data System/Likert 3-5) and Negative Initial Biopsy. A Mini Systematic Review. Eur Urol. 2022;82(5):452-457. https://doi.org/10.1016/j.eururo.2022.07.025
doi: 10.1016/j.eururo.2022.07.025
pubmed: 35985901
Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate imaging reporting and data system version 21: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019;76(3):340–351. https://doi.org/10.1016/j.eururo.2019.02.033
doi: 10.1016/j.eururo.2019.02.033
pubmed: 30898406
Klingebiel M, Schimmöller L, Weiland E, et al. Value of T2 mapping MRI for prostate cancer detection and classification. J Magn Reson Imaging. 2022;56(2):413-422. https://doi.org/10.1002/jmri.28061
doi: 10.1002/jmri.28061
pubmed: 35038203
Hepp T, Kalmbach L, Kolb M, et al. T2 mapping for the characterization of prostate lesions. World J Urol. 2022;40(6):1455-1461. https://doi.org/10.1007/s00345-022-03991-8
doi: 10.1007/s00345-022-03991-8
pubmed: 35357510
pmcid: 9166840
Hoang Dinh A, Souchon R, Melodelima C, et al. Characterization of prostate cancer using T2 mapping at 3T: a multi-scanner study. Diagn Interv Imaging. 2015;96(4):365-372. https://doi.org/10.1016/j.diii.2014.11.016
doi: 10.1016/j.diii.2014.11.016
pubmed: 25547670
Hilbert T, Sumpf TJ, Weiland E, et al. Accelerated T2 mapping combining parallel MRI and model-based reconstruction: GRAPPATINI. J Magn Reson Imaging. 2018;48(2):359-368. https://doi.org/10.1002/jmri.25972
doi: 10.1002/jmri.25972
pubmed: 29446508
Griswold MA, Jakob PM, Heidemann RM, et al. Generalized autocalibrating partially parallel acquisitions (GRAPPA). Magn Reson Med. 2002;47(6):1202-1210. https://doi.org/10.1002/mrm.10171
doi: 10.1002/mrm.10171
pubmed: 12111967
Roux M, Hilbert T, Hussami M, Becce F, Kober T, Omoumi P. MRI T2 Mapping of the Knee Providing Synthetic Morphologic Images: Comparison to Conventional Turbo Spin-Echo MRI. Radiology. 2019;293(3):620-630. https://doi.org/10.1148/radiol.2019182843
doi: 10.1148/radiol.2019182843
pubmed: 31573393
Gruenebach N, Abello Mercado MA, Grauhan NF, et al. Clinical feasibility and validation of the accelerated T2 mapping sequence GRAPPATINI in brain imaging. Heliyon. 2023;9(4):e15064. https://doi.org/10.1016/j.heliyon.2023.e15064
doi: 10.1016/j.heliyon.2023.e15064
pubmed: 37096006
pmcid: 10121777
Raudner M, Schreiner MM, Hilbert T, et al. Clinical implementation of accelerated T2 mapping: Quantitative magnetic resonance imaging as a biomarker for annular tear and lumbar disc herniation. Eur Radiol. 2021;31(6):3590-3599. https://doi.org/10.1007/s00330-020-07538-6
doi: 10.1007/s00330-020-07538-6
pubmed: 33274406
Vietti Violi N, Hilbert T, Bastiaansen JAM, et al. Patient respiratory-triggered quantitative T2 mapping in the pancreas. J Magn Reson Imaging. 2019;50(2):410-416. https://doi.org/10.1002/jmri.26612
doi: 10.1002/jmri.26612
pubmed: 30637852
pmcid: 6766866
Li S, Liu J, Zhang F, et al. Novel T2 mapping for evaluating cervical cancer features by providing quantitative T2 maps and synthetic morphologic images: A preliminary study. J Magn Reson Imaging. 2020;52(6):1859-1869. https://doi.org/10.1002/jmri.27297
doi: 10.1002/jmri.27297
pubmed: 32798294
Draveny R, Ambarki K, Han F, et al. Comparison of T2 Quantification Strategies in the Abdominal-Pelvic Region for Clinical Use. Invest Radiol. 2022;57(6):412-421. https://doi.org/10.1097/RLI.0000000000000852
doi: 10.1097/RLI.0000000000000852
pubmed: 34999669
Wenzel M, von Hardenberg J, Welte MN, et al. Monoprophylaxis With Cephalosporins for Transrectal Prostate Biopsy After the Fluoroquinolone-Era: A Multi-Institutional Comparison of Severe Infectious Complications. Front Oncol. 2021;11:684144. https://doi.org/10.3389/fonc.2021.684144
doi: 10.3389/fonc.2021.684144
pubmed: 34178678
pmcid: 8222717
Wenzel M, Theissen L, Preisser F, et al. Complication Rates After TRUS Guided Transrectal Systematic and MRI-Targeted Prostate Biopsies in a High-Risk Region for Antibiotic Resistances. Front Surg. 2020;7:7. https://doi.org/10.3389/fsurg.2020.00007
doi: 10.3389/fsurg.2020.00007
pubmed: 32185180
pmcid: 7059219
Wenzel M, Welte MN, Theissen LH, et al. Comparison of Complication Rates with Antibiotic Prophylaxis with Cefpodoxime Versus Fluoroquinolones After Transrectal Prostate Biopsy. Eur Urol Focus. 2021;7(5):980-986. https://doi.org/10.1016/j.euf.2020.11.006
doi: 10.1016/j.euf.2020.11.006
pubmed: 33358884
Wenzel M, Preisser F, Wittler C, et al. Correlation of MRI-Lesion Targeted Biopsy vs. Systematic Biopsy Gleason Score with Final Pathological Gleason Score after Radical Prostatectomy. Diagnostics (Basel). 2021;11(5). https://doi.org/10.3390/diagnostics11050882
Scherer J, Nolden M, Kleesiek J, et al. Joint imaging platform for federated clinical data analytics. JCO Clin Cancer Inform. 2020;4:1027-1038. https://doi.org/10.1200/CCI.20.00045
doi: 10.1200/CCI.20.00045
pubmed: 33166197
Ruprecht O, Weisser P, Bodelle B, Ackermann H, Vogl TJ. MRI of the prostate: interobserver agreement compared with histopathologic outcome after radical prostatectomy. Eur J Radiol. 2012;81(3):456-460. https://doi.org/10.1016/j.ejrad.2010.12.076
doi: 10.1016/j.ejrad.2010.12.076
pubmed: 21354732
Garcia-Reyes K, Passoni NM, Palmeri ML, et al. Detection of prostate cancer with multiparametric MRI (mpMRI): effect of dedicated reader education on accuracy and confidence of index and anterior cancer diagnosis. Abdom Imaging. 2015;40(1):134-142. https://doi.org/10.1007/s00261-014-0197-7
doi: 10.1007/s00261-014-0197-7
pubmed: 25034558
pmcid: 4419362
Yamauchi FI, Penzkofer T, Fedorov A, et al. Prostate cancer discrimination in the peripheral zone with a reduced field-of-view T(2)-mapping MRI sequence. Magn Reson Imaging. 2015;33(5):525-530. https://doi.org/10.1016/j.mri.2015.02.006
doi: 10.1016/j.mri.2015.02.006
pubmed: 25687187
pmcid: 4426240
Liu W, Turkbey B, Sénégas J, et al. Accelerated T2 mapping for characterization of prostate cancer. Magn Reson Med. 2011;65(5):1400-1406. https://doi.org/10.1002/mrm.22874
doi: 10.1002/mrm.22874
pubmed: 21394778
pmcid: 3079019
Liu L, Yin B, Shek K, et al. Role of quantitative analysis of T2 relaxation time in differentiating benign from malignant breast lesions. J Int Med Res. 2018;46(5):1928-1935. https://doi.org/10.1177/0300060517721071
doi: 10.1177/0300060517721071
pubmed: 29557239
pmcid: 5991255
Wu L-M, Yao Q-Y, Zhu J, et al. T2* mapping combined with conventional T2-weighted image for prostate cancer detection at 30T MRI: a multi-observer study. Acta Radiol. 2017;58(1):114–120. https://doi.org/10.1177/0284185116633916
doi: 10.1177/0284185116633916
pubmed: 26917785
Panda A, Obmann VC, Lo W-C, et al. MR fingerprinting and ADC mapping for characterization of lesions in the transition zone of the prostate gland. Radiology. 2019;292(3):685-694. https://doi.org/10.1148/radiol.2019181705
doi: 10.1148/radiol.2019181705
pubmed: 31335285